methyl 4-ethoxy-3-hydroxybenzoate | 91061-79-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 4-ethoxy-3-hydroxybenzoate
• 英文别名: Methyl 4-ethoxy-3-hydroxybenzoate
• CAS: 91061-79-9
• 化学式: C₁₀H₁₂O₄
• 分子量: 196.203
• InChiKey: GRZFGLXYGOYOOZ-UHFFFAOYSA-N

物化性质

• 沸点：
  339.1±22.0 °C(Predicted)
• 密度：
  1.180±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 4-ethoxy-3-hydroxybenzoate 在 吡啶 、 氯化亚砜 、 palladium 10% on activated carbon 、 氢气 、 硝酸 、 potassium carbonate 、 溶剂黄146 作用下， 以 甲醇 、 乙二醇甲醚 、 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 13.0h， 生成 4-((3-chloro-4-fluorophenyl)amino)-7-ethoxyquinazolin-6-yl acetate hydrochloride
  参考文献：
  名称：

  通过表皮生长因子受体激酶靶向的杂合剂对半胱氨酸进行镀铂。

  摘要：

  已经开发了杂化分子，其由酪氨酸激酶靶向的，基于喹唑啉的支​​架和柔性连接的dia（m）minechloridoPt（ii）部分组成。目标化合物对ErbB家族激酶蛋白保持高亲和力和选择性，并且其中一种衍生物诱导具有药理学上重要的半胱氨酸残基的铂加合物。

  DOI：

  10.1039/c8cc04251a
• 作为产物：
  描述：

  potassium phenolate 在 盐酸 、 氢溴酸 、 铜 作用下， 生成 methyl 4-ethoxy-3-hydroxybenzoate
  参考文献：
  名称：

  King, Journal of the Chemical Society, 1939, p. 1159

  摘要：

  DOI：

文献信息

• Structural Requirements for Factor Xa Inhibition by 3-Oxybenzamides with Neutral P1 Substituents:  Combining X-ray Crystallography, 3D-QSAR, and Tailored Scoring Functions
  作者：Hans Matter、David W. Will、Marc Nazaré,、Herman Schreuder、Volker Laux、Volkmar Wehner

  DOI：10.1021/jm049187l

  日期：2005.5.1

  The design, synthesis, and structure-activity relationship of 3-oxybenzamides as potent inhibitors of the coagulation protease factor Xa are described on the basis of X-ray structures, privileged structure motifs, and SAR information. A total of six X-ray structures of fXa/inhibitor complexes led us to identify the major protein-ligand interactions. The binding mode is characterized by a lipophilic dichlorophenyl substituent interacting with Tyr228 in the protease S1 pocket, while polar parts are accommodated in S4. This alignment in combination with docking allowed derivation of 3D-QSAR models and tailored scoring functions to rationalize biological affinity and provide guidelines for optimization. The resulting models showed good correlation coefficients and predictions of external test sets. Furthermore, they correspond to binding site topologies in terms of steric, electrostatic, and hydrophobic complementarity. Two approaches to derive tailored scoring functions combining binding site and ligand information led to predictive models with acceptable predictions of the external set. Good correlations to experimental affinities were obtained for both AFMoC (adaptation of fields for molecular comparison) and the novel TScore function. The SAR information from 3D-QSAR and tailored scoring functions agrees with all experimental data and provides guidelines and reasonable activity estimations for novel fXa inhibitors.
• Novel factor Xa inhibitors based on a benzoic acid scaffold and incorporating a neutral P1 ligand
  作者：Marc Nazaré、Hans Matter、Otmar Klingler、Fahad Al-Obeidi、Herman Schreuder、Gerhard Zoller、Jörg Czech、Martin Lorenz、Angela Dudda、Anusch Peyman、Hans Peter Nestler、Matthias Urmann、Armin Bauer、Volker Laux、Volkmar Wehner、David W. Will

  DOI：10.1016/j.bmcl.2004.03.059

  日期：2004.6

  A series of novel, highly potent, achiral factor Xa inhibitors based on a benzoic acid scaffold and containing a chlorophenethyl moiety directed towards the protease S1 pocket is described. A number of structural features, such as the requirements of the P1, P4 and ester-binding pocket ligands were explored with respect to inhibition of factor Xa. Compound 46 was found to be the most potent compound in a series of antithrombotic secondary assays. (C) 2004 Elsevier Ltd. All rights reserved.
• Functionalized Tyrosine Kinase Inhibitors Modified with Precious Metal Electrophiles and Methods Associated Therewith
  申请人：WAKE FOREST UNIVERSITY

  公开号：US20170081293A1

  公开（公告）日：2017-03-23

  Newly synthesized thiourea-modified 3-chloro-4-fluoroanilino-quinazoline derivatives have been studied as terminal carrier ligands in linear gold(I) complexes. The molecules mimic the tyrosine kinase inhibitor gefitinib (by computational docking experiments). Thiourea groups were either directly attached to quinazoline-C6 or linked to this position via a flexible ethylamino chain. One compound tested acts as a thiourea-S/quinazoline-N1 mixed-donor ligand, giving an unusual dinuclear complex as determined by X-ray crystallography and/or electrospray mass spectrometry. One compound formed the desired stable linear complex. The biological activity of the carrier ligands and corresponding gold(I) complexes was studied in NCI-H460 and NCI-H1975 lung cancer cells. One compound that was tested partially overcomes resistance to gefitinib in NCI-H1975 (with IC 50 values of 1.7 and 30 μM, respectively), and the corresponding gold complex (13) maintains activity in the low-micromolar concentration range.
• [EN] HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF<br/>[FR] COMPOSÉ DÉRIVÉ D'HÉTÉROARYLE ET SON UTILISATION<br/>[KO] 헤테로아릴 유도체 화합물 및 이의 용도
  申请人：[en]VORONOI INC.;[ko]보로노이 주식회사

  公开号：WO2022225238A1

  公开（公告）日：2022-10-27

  본 발명은 헤테로아릴 유도체 화합물 및 이의 용도에 관한 것이다. 본 발명의 헤테로아릴 유도체는 HER2 및 EGFR에 대해 우수한 억제 활성을 나타내므로, 상기 HER2 및/또는 EGFR 관련 질환의 치료제로 유용하게 사용될 수 있다.
• KR20220147021A
  申请人：——

  公开号：——

  公开（公告）日：——